PI3K Orchestrates T Follicular Helper Cell Differentiation in a Context Dependent Manner: Implications for Autoimmunity

Silvia Preite 1,2, Bonnie Huang 1,2, Jennifer L. Cannons 1,2, Dorian B. McGavern 3 and Pamela L. Schwartzberg 1,2*

1 National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, United States, 2 National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, United States, 3 National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, United States

T follicular helper (Tfh) cells are a specialized population of CD4+ T cells that provide help to B cells for the formation and maintenance germinal centers, and the production of high affinity class-switched antibodies, long-lived plasma cells, and memory B cells. As such, Tfh cells are essential for the generation of successful long-term humoral immunity and memory responses to vaccination and infection. Conversely, overproduction of Tfh cells has been associated with the generation of autoantibodies and autoimmunity. Data from gene-targeted mice, pharmacological inhibitors, as well as studies of human and mice expressing activating mutants have revealed that PI3Kδ is a key regulator of Tfh cell differentiation, acting downstream of ICOS to facilitate inactivation of FOXO1, repression of Klf2 and induction of Bcl6. Nonetheless, here we show that after acute LCMV infection, WT and activated-PI3Kδ mice (Pik3cdE1020K/+ ) show comparable ratios of Tfh:Th1 viral specific CD4+ T cells, despite higher polyclonal Tfh cells in Pik3cdE1020K/+ mice. Thus, the idea that PI3K activity primarily drives Tfh cell differentiation may be an oversimplification and PI3K-mediated pathways are likely to integrate multiple signals to promote distinct effector T cell lineages. The consequences of dysregulated Tfh cell generation will be discussed in the context of the human primary immunodeficiency “Activated PI3K-delta Syndrome” (APDS), also known as “p110 delta-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency” (PASLI). Overall, these data underscore a major role for PI3K signaling in the orchestration of T lymphocyte responses.

Keywords: Tfh cells, Tfr, ICOS, PI3K, APDS, PASLI, autoimmunity

INTRODUCTION

Naïve CD4+ T helper (Th) cells play pivotal roles in adaptive immunity through the differentiation into distinct cytokine-producing effector subsets that specifically fight a wide range of pathogens and tumors (1). T follicular helper (Tfh) cells provide help to B cells for the formation of germinal centers (GCs) (2–4), a specialized microenvironment where clonal expansion of B cells,
immunoglobulin diversification, affinity maturation, and development of memory B and long-lived plasma cells occur in response to immune challenge (5). The outcome of GC reactions requires proper help provided by Tfh cells (6–9). Most successful human vaccines are based on the generation of long-term protective humoral responses derived from the interactions of Tfh and GC B cells; however, Tfh cells can also promote dysregulated responses and autoimmunity (7, 10, 11). It is, therefore, critical to understand factors that promote or limit Tfh cells to elicit tightly controlled GC responses.

Recent data from gene-targeted mice, as well as mice and humans expressing activating mutants of phosphatidylinositol 3-kinase delta (PI3Kδ), suggest that PI3K activity is an essential component of pathways driving Tfh cell and GC formation (12–16). In this review, we discuss PI3Kδ-mediated pathways involved in the generation, maintenance and function of Tfh cells, including cellular receptors that activate PI3K within T cells, molecular pathways activated, and implications for autoimmunity, with a focus on the genetic disease APDS/PASLI.

**PI3K SIGNALING IN IMMUNITY**

**PI3K Signaling**

The PI3Ks are a family of heterodimeric lipid kinases that are activated downstream of a variety of receptors, including growth factor, antigen, costimulatory, cytokine, chemokine, and Toll-like receptors (17, 18). Class IA PI3Ks consist of a p85 regulatory and a p110 catalytic subunit that catalyzes the addition of a phosphate to the membrane phospholipid PI(4,5)P2, to generate phosphoinositide 3,4,5-triphosphate (PIP3). PIP3 helps recruit signaling molecules containing pleckstrin homology and other PIP3-binding domains to the plasma membrane to propagate signaling cascades (Figure 1). Mammals express three class IA catalytic isoforms: the broadly expressed p110α and p110β, and p110δ, which is expressed primarily by immune cells (17). Notably, PI3Kδ is activated by a variety of cell-surface receptors that are critical for Tfh cell differentiation, localization and function, including the T-cell receptor, CD28, and ICOS co-receptors, and cytokine receptors (17).

Activated-PI3K coordinates the recruitment of molecules such as PDK1 that phosphorylates and activates the serine/threonine kinase AKT, which in turn phosphorylates multiple targets. Among these are the FOXO transcription factors, which are then sequestered outside the nucleus by 14-3-3 proteins and degraded. FOXOs regulate transcription of multiple genes involved in lymphocyte development, differentiation and function (17, 20). Another downstream effector of PI3K is the mammalian Target of Rapamycin kinase (mTOR), which forms two complexes, mTORC1 and mTORC2, with different scaffolding partners (21). AKT activates mTORC1, an ancient regulator of metabolism, protein synthesis, and cell growth, mTORC2 is essential to fully phosphorylate and activate AKT, thus contributing to downstream signaling, including FOXO1 inactivation, and actin reorganization (21–23). PI3K is counteracted by the lipid-phosphatases PTEN and SHIP-1/2 that convert PIP3 to PI(4,5)P2 and PI(3,4)P2, respectively, (17) (Figure 1).

The importance of PI3Kδ in lymphocyte function is highlighted by the human primary immunodeficiency APDS/PASLI, in which patients are heterozygous for activating mutations in PIK3CD, the gene encoding p110δ. These patients show immunodeficiency and lymphopenia, as well as lymphoproliferation and autoimmunity (14, 15, 24, 25). Four independent groups, including us, have recently generated mouse models expressing the E1020K activating mutant of p110δ, which recapitulate many features of APDS/PASLI (16, 26–28). Notably, patients and Pik3cdE1020K/+ mice exhibit elevated circulating Tfh cells and GCs associated with autoantibody production (15, 16, 24, 29). Mice that express constitutively active p110α in T cells (30) or have a T cell-specific deletion of PTEN (13) also have elevated Tfh cell frequencies, supporting a more general connection between PI3K activity and Tfh cells. Nonetheless, the observation that p110δ-inactivation in T cells abrogates Tfh cell generation, supports a non-redundant role of p110δ in this process (12, 13). Together, these data provide strong evidence that PI3Kδ is an important component of pathways driving Tfh cell differentiation.

**Tfh Cell Differentiation**

The generation of Tfh cells is a multistage process that requires the integration of signals from different cell types (31). In the T cell zone of secondary lymphoid organs, antigen-presenting dendritic cells (DCs) activate T cells to initiate the pre-Tfh cell program, leading to induction of the costimulatory molecule ICOS and chemokine receptor CXCR5, as well as downregulation of CCR7, which together permit migration to the T-B cell border zone (32–34). Here, activated B cells receive signals from pre-Tfh cells to differentiate either along extra-follicular or GC pathways (5, 35). Cognate interactions with activated B cells help promote the differentiation into GC-Tfh cells (36), identified as CXCR5hiPD-1hiFoxp3- CD4+ T cells that also express high levels of ICOS, CD40L, and the Tfh-master transcription factor BCL-6, which are all critical for Tfh cell differentiation (37, 38). In turn, Tfh cells provide signals via costimulatory molecules and cytokines that help establish and maintain GCs. Thus, the generation of Tfh cells and GC reactions requires intimate communication between T and B cells involving multiple receptors that activate PI3K.

**ICOS-PI3K Pathways in Tfh Cells**

One of the key costimulatory receptors expressed by Tfh cells is ICOS, a CD28 family member. CD28 and ICOS both activate PI3Kδ and are required for Tfh cell development and function. CD28-CD80/CD86 interactions are involved in early T cell activation, including initial induction of ICOS, BCL-6, and CXCR5 (39), which are necessary for Tfh cell formation; Cd28−/− mice show a total absence of Tfh cells and thymus-dependent (TD) germinal centers (40–42). ICOS is upregulated on activated T cells shortly after TCR stimulation and interacts with ICOS-ligand (ICOS-L) on antigen presenting cells including DCs and B cells (43). Icos−/− and Icosil−/− mice display severely reduced humoral response to TD-antigens characterized by a lack of immunological memory and defective GC formation (44–49). Patients lacking ICOS display a common variable immunodeficiency (CVID) with
PI3K signaling pathways in Tfh cell differentiation. Class IA PI3Kα (PI3Kα), PI3Kβ (PI3Kβ), PI3Kδ (PI3Kδ) are lipid kinases composed by a regulatory (p85) and a catalytic (p110) subunit. Multiple receptors activate PI3K in CD4+ T cells, including TCR, CD28, ICOS, OX-40 and IL-21R, leading to PI3K recruitment to the plasma membrane and conversion of the membrane lipid P(4,5)P2 to P(3,4,5)P3. In T cells, chemokine receptors, including CXCR5, preferentially drive the activation of the class IB PI3Kγ (19). PI3K activity is counteracted by the inhibitor receptor PD-1 that blocks CD28 signal transduction through SHP-2 recruitment and PTEN induction. The phosphatases PTEN and SHIP-1/2 counteract PI3K signaling by converting PIP3 to P(4,5)P2 and P(3,4)P2, respectively. PIP3 recruits to the plasma membrane proteins containing pleckstrin homology domains, such as AKT and PDK1. The serine/threonine kinase AKT gets activated by phosphorylation by PDK1 (at Thr308) and mTORC2 (at Ser473). In turn, activated pAKT phosphorylates inhibitors of mTORC1 leading to its activation. mTORC1 phosphorylates several factors including S6-kinase (S6K), that phosphorylates S6, driving protein synthesis and cell proliferation, important events for Tfh cell differentiation. pAKT also phosphorylates the FOXO-1 transcription factor leading to its export outside the nucleus and degradation by binding 14-3-3 proteins. FOXO-1 represses Bcl6, essential for Tfh cells, and promotes expression of multiple genes including Sell, Tcf7, Ccr7, and Klf2. While KLF-2 represses Tfh cell formation by inhibiting Il-2ra, Blimp1, Ilfg. At the same time, it has been shown that mTORC2-pAkt may also support TCF-1 activity through the inactivation of GSK3β, an inhibitor of β-catenin and TCF-1. Overall, PI3K pathways drive BCL-6+ Tfh cell differentiation that coordinates GC responses and humoral immunity after infections and vaccination through the generation of memory B cells and long-lived plasma cells (LLPC).

The essential role of PI3K in ICOS function was highlighted by data showing that mutation of the p85-binding site, which selectively abrogates PI3K recruitment, led to defects in Tfh cell formation similar to ICOS-deficiency (56). Inhibition of p110δ also prevented ICOS-mediated changes in cell migration and morphology in vitro (55). Conversely, we found that activated-PI3Kδ mice show T cell-intrinsic increases in Tfh cell differentiation, even in the presence of blocking anti-ICOS-L antibody, therefore bypassing the requirement for ICOS for Tfh cell development (16). Thus, PI3K appears to be a major effector of ICOS, required for Tfh cell formation and maintenance.
PI3K Signaling Downstream of ICOS

After ICOS ligation, activated-PI3Kδ transduces its signals through several intermediates, including pAKT-mediated inactivation of FOXO1 (20). FOXO1 transcriptionally represses Bcl6, a driver of Th cell differentiation (30, 57, 58); strong PI3K activity relieves this repression. FOXO1 also transcriptionally activates Klf2 (59), which restrains Tfh cells and promotes alternative T helper subsets through at least four mechanisms: (1) induction of Slpr, downregulation of which is essential for Tfh cell retention in GC and efficient polarization; (2) induction of BLIMP1, which negatively regulates Bcl6 and Tfh cell generation; (3) induction of T-bet and GATA3 which drives Th1 and Th2 cell differentiation, respectively; and (4) repression of Cxcr5 (39, 60). Accordingly, Foxo1−/− CD4+ T cells generate increased percentages of pre-Tfh cells (CXCR5intBCL-6int) early post-immunization, even in the presence of anti-ICOS-L (57), similar to cells expressing activated-PI3Kδ (16). These data support the ICOS-PI3Kδ-FOXO1 pathway as critical for Tfh cell development; accordingly, Pik3cdR1020K+/+ CD4+ T cells exhibit elevated pFOXO1 upon TCR stimulation, even without further ICOS re-stimulation (16). Furthermore, an AKT-resistant mutant of FOXO1 prevents increased Tfh cells in the presence of activated-PI3Kδ (16). It is also of note that ICOS is a stronger inducer of PI3K than CD28, resulting in greater inhibition of FOXO1; this may account for the inability of CD28 to compensate for ICOS-deficiency in promoting Tfh cells (39, 42, 56, 61, 62). However, Foxo1−/− T cells show defective GC-Tfh (CXCR5highBCL-6high) cell formation (57) which is not observed with activated-PI3Kδ (16). Thus, cells expressing activated-PI3Kδ likely still retain some FOXO1 activity. FOXO1 is required for sustained surface ICOS expression (57), providing a possible explanation for this defect. Indeed, chromatin immunoprecipitation and deep sequencing revealed FOXO1 binding sites in multiple genes that influence Tfh cell fate, including Cxcr4, Batf, Irf4, Icos, and Prdm1 (57, 63).

Nonetheless, despite increased GC-Tfh cell differentiation, Pik3cdR1020K+/+ mice show disorganized GCs with increased Tfh cell infiltration and impaired class-switched antigen-specific responses to immunization (16, 27, 28). Multiple factors may contribute to these poor responses, including impaired B cell selection due to increased Tfh cells (7) and Tfh cell mislocalization (16), or intrinsic B cell defects. Indeed, although deletion of p110δ in B cells only minimally affected GC formation and T cell-dependent humoral responses after protein immunization (13), activated-PI3Kδ drove B cell-intrinsic increases in GC B and plasma cells, as well as impaired class-switched antibody production (16, 28). Increased GC B cells may in turn further drive expanded Tfh cell numbers, contributing to immune dysregulation. Additionally, increased GCs that fill the follicular dendritic cell network at baseline, may prevent new GC formation as mice age (16). Whether and how FOXO1 contributes to defects in antigen-specific responses or whether additional downstream effectors of PI3K are involved remain intriguing questions. It should also be noted that additional receptors expressed by Tfh cells, including OX-40, and IL-21R activate PI3K (64) and may contribute to expanded Tfh cell populations in these mice; in contrast, PD-1, an inhibitory receptor highly expressed by Tfh cells (65), counteracts PI3K by blocking CD28 signaling and increasing PTEN expression (66–69) (Figure 1).

CONTEXT-DEPENDENT ROLES FOR PI3K IN T CELL DIFFERENTIATION

Viral Infection

Although the connection between ICOS and PI3Kδ provides strong evidence for PI3Kδ driving Tfh cells, the view that PI3Kδ exclusively promotes Tfh cells may be a simplification; this is particularly apparent when looking at the differentiation of Tfh vs. Th1 cells during viral infection. In response to viral or strong Th1 polarizing infections, CD4+ T cells undergo an early bifurcation such that up to 50% of viral-specific T cells express BCL-6 and become Tfh cells, while the rest express BLIMP1 and SLAM, and become IFNγ-producing Th1 cells (54). Although activated-PI3Kδ increased percentages of Tfh cells at baseline and in response to immunization (16), as well as polyclonal CXCR5+PD-1+ Tfh cells after LCMV infection (Figure 2A), it did not alter Tfh cell percentages, nor Thf/Th1 ratios, within viral-specific GP66-tetramer+ CD4+ T cells in the same mice (Figures 2B, C). We also observed increased percentages of circulating CXCR3+ Tfh1 cells in patients with APDS/PASLI compared to controls (16), suggesting that PI3Kδ can drive both Tfh cells and Type 1 immunity. Thus, PI3Kδ activity may promote multiple effector T cell lineages and the effects of PI3K on Tfh cells may depend on the activating stimuli and microenvironment.

IL2 Signaling

Among potential PI3K-mediated signaling pathways that influence Tfh and Th1 cell differentiation are those downstream from the cytokine IL-2. Early data suggested that PI3K is activated by the IL-2R signaling complex (71–73); PI3K inhibitors arrest IL-2 induced CTL growth (74, 75). However, recent reports question the direct connection between IL-2 and PI3K activation (76), as that: (1) certain PI3K inhibitors (such as LY294002) have off-target effects (77); (2) many studies evaluate pAKT(S473) and pS6, rather than pAKT(T308) which more accurately reflects PI3K activity (78); and (3) IL-2 can promote mTORC1 activation independent of PI3K (79). Indeed, IL-2 potently inhibits Tfh cell generation via STAT3-mediated induction of BLIMP1 (80–82); BLIMP1+ Tfh1 cells express high levels of the high-affinity IL-2 receptor, CD25, and pSTAT5. As that IL-2 activates multiple signaling pathways, the integration, kinetics, and balance of these and other signals elicited in response to multiple receptors, may ultimately help determine T helper cell fates.

Metabolic Pathways in Tfh vs. Th1 Cells

Other PI3K-mediated signaling pathways that may influence both Tfh and Th1 cells are those involving mTORC1 and mTORC2. During acute LCMV infection, Th1 cells appear more proliferative and bio-energetically demanding with greater glucose metabolism and metabolic respiration than Tfh cells (83). Data suggest that these Th1 cells were more dependent
on the IL-2-PI3K-AKT-mTORC1 axis, which preferentially promoted BLIMP1+ Th1 cells at the expense of BCL-6+ Tfh cells and humoral immunity (83, 84). However, other studies have demonstrated requirements for mTORC1 and mTORC2 in driving Tfh cells in Peyer’s Patches at steady state and in the periphery after LCMV infection and immunization (30, 85). Mechanistically, Tfh cells were supported by mTORC1-promotion of pS6, GLUT1 expression, glycolysis, lipogenesis and overall proliferation; and by mTORC2-pAKT, which decreased FOXO1 activity (30).

While these studies provide conflicting conclusions on the requirements for PI3K and downstream effectors for Tfh cells, this may result from different experimental systems (knockdown vs. knockout) as well as bio-energetic demands during immune challenges. However, there is also evidence that mTOR may be activated independently of PI3K via pathways involving nutrient sensing that may also affect T helper cell differentiation (22, 79, 86, 87).

**PI3K-TCF-1 Cross-Talk**

Several recent studies revealed that the transcription factor TCF-1 is expressed at high levels in Tfh cells after viral infection and plays an essential role in their generation and maintenance, via repression of Il2ra, and Prdm1 (which encodes BLIMP1), promotion of Bcl6 (55, 88–90), and possibly repression of Ifng (91). Intriguingly, PI3K has been implicated both positively and negatively in TCF-1 regulation (92, 93). In CD8+ T cells, Tcf7, which encodes for TCF-1, is induced by FOXO1 (94), and both are required for memory T cell formation (95–98). Strong PI3K signaling would therefore be expected to decrease TCF-1 levels (25), as observed in studies of asymmetric cell division (92, 93). Conversely, a positive link between PI3K/AKT and TCF-1 has been proposed via β-catenin (85), a coactivator of TCF-1 that is negatively regulated by phosphorylation by Glycogen Synthase Kinase 3β (GSK3β), which is inactivated by pAKT (Figure 1). mTORC2-deficient T cells, which do not fully activate AKT, show reduced β-catenin and TCF-1 (85). Nonetheless, most studies implicating TCF-1 in Tfh cell generation have been done in the context of strong Th1-inducing infections (88–90), and how these findings relate to Tfh cells in other contexts remains unknown. Thus, the relationship between PI3K and TCF-1, how they affect Tfh cell differentiation, and involvement in possible feedback loops remain intriguing questions.

**PI3K PATHWAYS IN Tfr CELLS**

A subset of thymic derived T regulatory cells, defined as T follicular regulatory (Tfr) cells, are localized at the T-B cell border and inside the GC area (99), and directly control the activation and differentiation of Tfh and GC B cells, including the development of autoimmunity (100). Tfr cells are phenotypically similar to Tfh cells and express BCL-6 (101–103), yet lack expression of B-cell-helper molecules, such as CD40L, and express inhibitory molecules CTLA-4, GITR, IL-10, and granzymes (104). Although excessive PI3K-mTOR activity is detrimental for induced-Treg cell differentiation (105–107),
Pik3cdΔ1020K/+ mice show increased Treg and Tfr cells at steady state (16, 26). Indeed, although Tfr cells derive from Tregs, Tfr cells have different requirements for their differentiation and function. For example, IL-2 is necessary for Treg development and suppressive capability (108), yet prevents Tfr cell differentiation in a BLIMP1-dependent manner, similar to IL-2’s effects on Tfh cells (109). Tfr cells also display high mTORC1 activity that promotes differentiation and STAT3 phosphorylation, which induces Tcf7 and Bcl6 (110); increased Akt-mTOR activity in Roquin-deficient Treg cells upregulates Tfh cell gene signatures that drive Tfr cell differentiation (111). How PI3K affects ratios of Tfh:Tfr cells, which are important for regulating humoral responses and autoimmunity (104), is less clear; notably, Pik3cdΔ1020K/+ mice have parallel increases in both cell populations (16).

**DYSREGULATED PI3K PATHWAYS IN AUTOIMMUNITY**

In addition to helping antigen-specific humoral responses to vaccination and infection, Tfh cells have been linked to autoimmunity in both animals and humans (10, 112). Correlations between circulating Tfh (cTfh) cells and disease have been reported in systemic lupus erythematosus (SLE) (113), rheumatoid arthritis (RA) and Sjögren’s syndrome (112). Similarly, APDS/PASLI patients have high cTfh cells (16), and autoimmune manifestations including autoantibodies, cytopenias and glomerulonephritis (15, 29). In parallel, we found that Pik3cdΔ1020K/+ mice develop autoantibodies against a wide range of self-antigens. Indeed, PIDs caused by mutations affecting PI3K stimulating cascades, or “immune TOR-opathies,” often display a combination of defective immune-responses and autoimmunity (114); animal models demonstrate that PI3K activity in B cells, T helper and regulatory T cells contributes to autoimmune manifestations (16, 115–121). Additionally, increased PI3K activity has been observed in several autoimmune diseases (121), and inhibitors of PI3Kδ and PI3Kγ are currently being explored in pre-clinical models of RA and SLE, and clinically for psoriasis (NCT02303509) and Sjögren’s (NCT02775916) (121, 122).

Recently data suggest that certain autoantibodies cross-react with gut microbiota, supporting links between the microbiome and autoimmunity (123). Interestingly, we found increased local and systemic immune responses against gut commensals in Pik3cdΔ1020K/+ mice, with evidence for cross-reactivity between anti-self and anti-bacterial antibodies. Furthermore, autoantibodies could be prevented by systemic antibiotic treatment (16). Such data highlight roles for PI3Kδ in modulating T and B lymphocyte activation, including that induced by the microbiota, which can lead to autoimmunity.

**CONCLUDING REMARKS**

Together, a growing body of evidence supports a connection between PI3Kδ and Tfh cell differentiation, raising the possibility that altered PI3K pathways may contribute to both immunodeficiency and autoimmunity. Nonetheless, results during viral infection suggest that effects of PI3K on Tfh cell differentiation may be context-dependent and that PI3K may promote multiple effector cell lineages. A recent report demonstrated that treatment of APDS/PASLI patients with leniolisib, a selective PI3Kδ inhibitor, showed promising improvements in cellular dysfunction and lympho-proliferation (124). Notably, selective PI3Kδ inhibition reduced serum IgM *in vivo* (124), while increasing IgG class-switching *in vitro* (16, 27); however, effects on Tfh cells and autoantibodies have not yet been reported. Our results further suggest that evaluation of microbiota composition and systemic responses to gut commensals in APDS/PASLI may provide new opportunities, possibly in association with leniolisib, for managing this and other conditions where Tfh cells and autoantibodies contribute to pathogenesis. Such approaches may also be relevant for autoimmunity induced by checkpoint-blockade therapy, where PI3Kδ-inhibition may provide a selective control of immune responses. Finally, PI3Kδ activation may help improve vaccine responses, although this would have to be carefully assessed. Thus, a more comprehensive understanding of PI3K regulation and signaling in T and B cells is of crucial importance to more effectively improve humoral immune responses while minimizing autoimmunity.

**METHODS**

**Animal Care and Ethics**

Control (C57Bl/6J) and Pik3cdΔ1020K/+ mice (16) were maintained and treated under specific pathogen-free (SPF) conditions under protocols reviewed and approved by the NINDS (protocol 1295-12) and NHGRI (protocol G98-3) Animal Care and Use Committees at the NIH.

**LCMV Infection and Flow-Cytometry**

Mice were injected intravenously (i.v.) with 2×10⁵ plaque-forming units (PFUs) of LCMV Armstrong, kindly provided by Dorian McGavern Lab, grown as previously described (88). Day+7/8 post infection, single cell suspensions were prepared from spleen in MACS buffer (PBS with 2% FBS and 2 μM EDTA). GP66 tetramer [I-A(b) QVYSLIRPNENPAHK] PE was obtained from NIH tetramer facility (Emory University); staining was performed at 37°C for 1 h in RPMI with 10% serum. CXCR5 staining was performed using; CXCR5-purified (2G8, BD Biosciences), followed by Biotin-SP AffiniPure Fab Fragment Goat Anti-Rat IgG (H+L) (Jackson ImmunoResearch), and Streptavidin (BioLegend) as previously described (88). The following antibodies (obtained from BioLegend, BD Biosciences, eBioscience) were incubated with spleen cells for 45/60 min on ice: CD4 (RM4-5), B220 (RA3-6B2), PD-1 (RMP1-30), SLAM (TC15-12F12.2). Intracellular staining of Foxp3 (FJK-16s) was performed using the Foxp3-staining buffer (eBioscience). Cells were gated according to FSC-A/SSC-A, doublet exclusion (SSC-H/SSC-W and FSC-H/FSC-W), live cells (negative for LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit, Life Technologies), followed by gating strategies indicated in figure legend. Flow cytometry was performed on a LSRII (BD

---

**Figure Legend**

Flow cytometry was performed on a LSRII (BD Technologies), followed by gating strategies indicated in figure legend.
Biosciences) and data analyzed using FlowJo 9.9 software (TreeStar).

**Statistical Analysis**

Data were analyzed via Prism 6 (GraphPad Software) using non-parametric unpaired Mann-Whitney U-test. Graphs show the mean ± SEM. *P < 0.05; ** P < 0.01; *** P < 0.001. If not indicated, the P-values were not significant (>0.05).

**AUTHOR CONTRIBUTIONS**

SP designed and performed experiments, analyzed and interpreted data, wrote the manuscript and prepared the figures. BH and JLC performed experiments, edited the manuscript, and contributed to discussions. DBM contributed essential reagents and advice. PLS conceived the project, wrote the manuscript, and provided overall direction of the study. All authors concur with this submission.

**FUNDING**

This work was supported in part by funds from the intramural programs of the National Human Genome Research Institute, National Institute of Allergy and Infectious Diseases and National Institute of Neurological Disorders and Stroke, NIH.

**ACKNOWLEDGMENTS**

We thank members of the PLS and DBM labs for their assistance with this work. GP66 tetramer [I-A(b) QVYSLIRPNENPAHK PE] was obtained from the NIH tetramer facility (Emory University).

**REFERENCES**

1. Sallusto F. Heterogeneity of human CD4(+) T cells against microbes. *Annu Rev Immunol.* (2016) 34:317–34. doi: 10.1146/annurev-immunol-032414-112056

2. Vinuesa CG, Linterman MA, Goodnow CC, Randall KL. T cells and follicular dendritic cells in germinal center B-cell formation and selection. *Immunol Rev.* (2010) 237:72–89. doi: 10.1111/j.1600-065X.2010.00937.x

3. Crotty S. Follicular helper CD4 T cells (TFH). *Annu Rev Immunol.* (2011) 29:621–63. doi: 10.1146/annurev-immunol-031210-101400

4. Cannons JL, Lu KT, Schwartzberg PL. T follicular helper cell diversity and plasticity. *Trends Immunol.* (2013) 34:200–7. doi: 10.1016/j.ti.2013.01.001

5. Mesin L, Ersching J, Victora GD. Germinal center B cell dynamics. *Immunity* (2016) 45:471–482. doi: 10.1016/j.immuni.2016.09.001

6. Pratama A, Vinuesa CG. Control of TFH cell numbers: why and how? *Immunol Cell Biol.* (2014) 92:40–8. doi: 10.1038/icb.2013.69

7. Preite S, Baumjohann D, Foglietani M, Basso C, Ronchi F, Fernandez Rodriguez BM, et al. Somatic mutations and affinity maturation are impaired by excessive numbers of T follicular helper cells and restored by Tre2 cells or memory T cells. *Eur J Immunol.* (2015) 45:3010–21. doi: 10.1002/eji.201549920

8. Brink R, Phan TG. Self-reactive B cells in the germinal center reaction. *Annu Rev Immunol.* (2018) 36:339–57. doi: 10.1146/annurev-immun-051116-052510

9. Baumjohann D, Preite S, Reboldi A, Ronchi F, Ansel KM, Lanzavecchia A, et al. Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. *Immunity* (2013) 38:596–605. doi: 10.1016/j.immuni.2012.11.020

10. Ueno H. T follicular helper cells in human autoimmunity. *Curr Opin Immunol.* (2016) 43:24–31. doi: 10.1016/j.coi.2016.08.003

11. Brink R. The imperfect control of self-reactive germinal center B cells. *Curr Opin Immunol.* (2014) 28:97–101. doi: 10.1016/j.coi.2014.03.001

12. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. *Nat Rev Immunol.* (2003) 3:317–30. doi: 10.1038/nri1056

13. Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K Pathway in Human Disease. *Cell* (2017) 170:605–35. doi: 10.1016/j.cell.2017.07.029

14. Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, Cyster JG. Cutting edge: differential roles for phosphoinositide-3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. *J Immunol.* (2004) 173:2236–40. doi: 10.4049/jimmunol.173.4.2236

15. Hedrick SM, Hess Michelle R, Doedens AL, Goldrath AW, Stone EL. FOXO transcription factors throughout T cell biology. *Nat Rev Immunol.* (2012) 12:649–61. doi: 10.1038/nrri3278

16. Ueno H. T follicular helper cells in human autoimmunity. *Curr Opin Immunol.* (2016) 43:24–31. doi: 10.1016/j.coi.2016.08.003

17. Brink R. The imperfect control of self-reactive germinal center B cells. *Curr Opin Immunol.* (2014) 28:97–101. doi: 10.1016/j.coi.2014.03.001

18. Okkenhaug K, Bilancio A, Preite S, Kapnick SM, Uzel G, Schwartzberg PL. Genetic defects in phosphoinositide 3-kinase delta influence CD8(+) T cell survival, differentiation, and function. *Front Immunol.* (2018) 9:1758. doi: 10.3389/fimmu.2018.01758

19. Stark AK, Chandra A, Chakraborty K, Alam R, Carbonaro V, Clark J, et al. PI3KDelta hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner. *Nat Commun.* (2018) 9:3174. doi: 10.1038/s41467-018-05674-8

20. Avery DT, Kane A, Nguyen T, Lau A, Nguyen A, Lenthall H, et al. Germline-activating mutations in PIK3CD compromise B cell development and function. *J Exp Med.* (2018) 215:2073–95. doi: 10.1084/jem.20180010

21. Wray-Dutra MN, Al Qureshah F, Metzler G, Ouakka M, James RG, Rawlings DJ. Activated PIK3CD drives innate B cell expansion yet limits B cell-intrinsic immune responses. *J Exp Med.* (2018) 215:2485–96. doi: 10.1084/jem.20180617
29. Coulter TL, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study. J Allergy Clin Immunol. (2017) 139:597–606.e4. doi: 10.1016/j.jaci.2016.06.021

30. Zeng H, Cohen S, Guy C, Shrestha S, Neale G, Brown SA, et al. mTORC1 and mTORC2 kinase signaling and glucose metabolism drive follicular helper T cell differentiation. Immunity. (2016) 45:540–54. doi: 10.1016/j.immuni.2016.08.017

31. Qi H. T follicular helper cells in space-time. Nat Rev Immunol. (2016) 16:612–25. doi: 10.1038/nri.2016.94

32. Goenka R, Barnett LG, Silver JS, O’Neill PJ, Hunter CA, Cancro MP, et al. Cutting edge: dendritic cell-restricted antigen presentation initiates the follicular helper T cell program but cannot complete ultimate effector differentiation. J Immunol. (2011) 187:1091–5. doi: 10.4049/jimmunol.1100853

33. Baumjohann D, Okada T, Ansel KM. Cutting edge: distinct waves of BCL6 expression during T follicular helper cell development. J Immunol. (2011) 187:2089–92. doi: 10.4049/jimmunol.1101393

34. Allen CD, Ansel KM, Low C, Lesley R, Tamamura H, Fujii N, et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Immunity. (2004) 5:943–52. doi: 10.1016/S1074-7613(04)00140-3

35. MacLennan IC, Toellner KM, Cunningham AF, Serre K, Sze DM, Zuniga E, et al. Extrafollicular antibody responses. ImmunoL Rev. (2004) 198:1–18. doi: 10.1111/j.1600-065X.2003.00568.x

36. Ma CS, Deenick EK, Batten M, Tangye SG. The origins, function, and regulation of T follicular helper cells. J Exp Med. (2012) 210:1241–53. doi: 10.1084/jem.20120994

37. Crotty S. T follicular helper cell differentiation, function, and roles in disease. Nat Rev Immunol. (2014) 14:529–42. doi: 10.1038/nri.2014.10.004

38. Cannons JL, Tangye SG, Schwartzberg PL. SLAM family receptors and SAP adaptors in immunity. Annu Rev Immunol. (2011) 29:665–705. doi: 10.1146/annurev-immunol-031010-103100

39. Weber JP, Fuhrmann F, Feist RK, Lahnmann A, Al Baz MS, Gentz LJ, et al. ICOS maintains the T follicular helper cell phenotype by down-regulating Kruppel-like factor 2. J Exp Med. (2015) 212:217–33. doi: 10.1084/jem.20141432

40. Mitttrucker HW, Kohler A, Mak TW, Kaufmann SH. Critical role of CD28 in protective immunity against Salmonella typhimurium. J Immunol. (1999) 163:6769–76.

41. Shahinian A, Pfeffer K, Lee KP, Kundig TM, Kishihara K, Wakeham A, et al. ICOS coreceptor signaling inactivates the transcription factor Foxo1 in activated T cells. J Immunol. (2011) 187:2099–204. doi: 10.4049/jimmunol.1101393

42. Arimura Y, Kato H, Dianzani U, Okamoto T, Kamekura S, Buonfiglio D, et al. A co-stimulatory molecule on activated T cells, H4/ICOS, delivers signals that regulate the differentiation of T follicular helper cells and autoimmunity. Nature. (2003) 420:256–62. doi: 10.1038/nature01205

43. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Rolf J, Fairfax K, Turner M. Signaling pathways in T follicular helper cells. Int Immunol. (2001) 13:555–66. doi: 10.1093/intimm/dxf022

44. Tafuri A, Shahinian A, Bladt F, Yoshinaga SK, Kamekura S, Buonfiglio D, et al. Costimulation through the inducible costimulator ligand is essential for both T helper and B cell functions in T cell-dependent B cell responses. J Immunol. (2002) 169:5205–13. doi: 10.4049/jimmunol.169.10.5205

45. Mak TW, Shahinian A, Yoshinaga SK, Wakeham A, Boucher LM, Pintilie M, et al. Inducible costimulator promotes helper T-cell differentiation through phosphoinositide 3-kinase. Proc Natl Acad Sci USA. (2009) 106:20371–6. doi: 10.1073/pnas.0911573106

46. Stone EL, Pepper M, Katayama CD, Kerdiles YM, Lai CY, Emslie E, et al. ICOS coreceptor signaling inactivates the transcription factor FoxO1 to promote Th cell differentiation. Immunity. (2015) 42:239–51. doi: 10.1016/j.immuni.2015.01.017

47. Dong C, Teman UA, Flavell RA. Cutting edge: critical role of inducible costimulator in germinal center reactions. J Immunol. (2001) 166:6569–62. doi: 10.4049/jimmunol.166.6.6569

48. Rolf J, Fairfax K, Turner M. Signaling pathways in T follicular helper cells. Int Immunol. (2001) 13:555–66. doi: 10.1093/intimm/dxf022

49. Akiba H, Takeda K, Kojima Y, Usui Y, Harada N, Yamazaki T, et al. The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo. J Immunol. (2005) 175:2340–8. doi: 10.4049/jimmunol.175.4.2340

50. Grimbacher B, Hutloff A, Schlesier M, Gloeker E, Warnatz K, Drager R, et al. Homologous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol. (2003) 4:261–8. doi: 10.1038/nri902

51. Yu D, Tan AH, Hu X, Athanasopoulos V, Simpson N, Silva DG, et al. Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature. (2007) 450:299–303. doi: 10.1038/nature06253

52. Yu D, Tan AH, Hu X, Athanasopoulos V, Simpson N, Silva DG, et al. Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature. (2007) 450:299–303. doi: 10.1038/nature06253

53. Vinuesa CG, Cook MC, Angelucci C, Athanasopoulos V, Rui L, Hill KM, et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature. (2003) 435:452–8. doi: 10.1038/nature03555

54. Choi YS, KayeYama R, Eto D, EscoBar TC, Johnston RJ, Monticelli L, et al. ICOS receptor initiators T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity. (2011) 33:932–46. doi: 10.1016/j.immuni.2011.03.023

55. Parry RV, Rumbley CA, Vandenberghe LH, June CH, Riley JL. CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J Immunol. (2003) 169:637–44. doi: 10.4049/jimmunol.169.2.637
67. Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science (2017) 355:1428–33. doi: 10.1126/science.aai1292
68. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of regulatory T cells. J Exp. Med. (2009) 206:3015–29. doi: 10.1084/jem.20090984
69. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls follicular T helper cell positioning and function. Immunity (2019) 49:264–74.e4. doi: 10.1016/j.immuni.2019.06.012
70. Tian Y, Mollo SB, Harrington LE, Zajac AJ. IL-10 Regulates Memory T Cell Development and the balance between Th1 and follicular Th cell responses during an acute viral infection. J Immunol. (2016) 197:1308–21. doi: 10.4049/jimmunol.1502481
71. Migone TS, Rodig S, Cacalano NA, Berg M, Schreiber RD, Leonard WJ. Functional cooperation of the interleukin-2 receptor beta chain and Jak1 in phosphatidylinositol 3'-kinase recruitment and phosphorylation. Mol Cell Biol. (1998) 18:6416–22. doi: 10.1128/MCB.18.11.6416
72. Truitt KE, Mills GB, Turck CW, Imboden JB. SH2-dependent association of phosphatidylinositol 3'-kinase with the interleukin-2 receptor beta chain. J Biol Chem. (1994) 269:5937–43.
73. Gu H, Maeda H, Moon JJ, Lord JD, Yoakim M, Nelson BH, et al. New role of phosphatidylinositol 3'-kinase 85-kDa regulatory subunit with the interleukin-2 receptor beta chain. J Biol Chem. (1994) 269:5937–43.
74. Ross SH, Cantrell DA. Signaling and function of interleukin-2 receptor beta chain. Annu Rev Immunol. (2018) 36:411–33. doi: 10.1146/annurev-immunol-042618-055352
75. Jacobs MD, Black J, Futer O, Swenson L, Hare B, Fleming M, et al. Functional cooperation of the interleukin-2 receptor beta chain and Jak1 in phosphatidylinositol 3'-kinase recruitment and phosphorylation. Mol Cell Biol. (1998) 18:6416–22. doi: 10.1128/MCB.18.11.6416
76. Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T follicular helper cell differentiation. J Exp Med. (2011) 208:224–36. doi: 10.1084/jem.20110212
77. Yang J, Lin X, Pan Y, Wang J, Chen P, Huang H, et al. Critical roles of mTOR Complex 1 and 2 for T follicular helper cell differentiation and germinal center responses. Ebiol. (2016) 5:e17936. doi: 10.15544/lfe.17936
78. Macintyre AN, Finlay D, Preston G, Sinclair LV, Vaugh CM, Tamás P, et al. Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity (2011) 34:224–36. doi: 10.1016/j.immuni.2011.01.012
79. Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of regulatory T cells. J Exp. Med. (2009) 206:3015–29. doi: 10.1084/jem.20090984
80. Preite et al. PI3K in Tfh Cells
81. Ballesteros-Tato A, Leon B, Graf BA, Moquin A, Adams PS, Lund KE. SH2-dependent association of phosphatidylinositol 3'-kinase with the interleukin-2 receptor beta chain. J Biol Chem. (1994) 269:5937–43.
82. Grzes KM, Swamy M, Hukelmann JL, Emslie E, Sinclair LV, Cantrell DA. Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy. Leukemia (2017) 31:2771–9. doi: 10.1038/leu.2017.160
83. Wu T, Shin HN, Moseman EA, Ji Y, Huang B, Harly C, et al. TCF1 Is Required for the T Follicular Helper Cell Response to Viral Infection. Cell Rep. (2015) 12:2099–110. doi: 10.1016/j.celrep.2015.08.049
84. Sage PT, Sharpe AH. T follicular regulatory cells. J Exp Med. (2015) 215:1189–200. doi: 10.1084/jem.20151047
85. Lin WH, Adams WC, Nish SA, Chen YH, Yen B, Rothman NJ, et al. Asymmetric PI3K signaling driving developmental and regenerative cell fate bifurcation. Cell Rep. (2015) 13:2203–18. doi: 10.1016/j.celrep.2015.10.072
86. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates differentiation of CD4 T helper 1 and follicular B helper T cells. J Exp Med. (2005) 209:2441–53. doi: 10.1084/jem.20051260
87. Macintyre AN, Finlay D, Preston G, Sinclair LV, Vaugh CM, Tamás P, et al. Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity (2011) 34:224–36. doi: 10.1016/j.immuni.2011.01.012
88. Wu T, Ji Y, Moseman EA, Xu HC, Manglani M, Kirby M, et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci Immunol. (2016) 1:eaa8853. doi: 10.1126/sciimmunol.aaa8853
89. Hess Michelin R, Doedens AL, Goldrath AW, Hedrick SM. Differentiation of CD8 memory T cells depends on Foxo3. J Exp Med. (2019) 214:1189–200. doi: 10.1084/jem.20193092
90. Jeannot G, Boudousquier C, Gardiol N, Kang J, Huelsken J, Held W. Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8+ T cell memory. Proc Natl Acad Sci USA. (2010) 107:9777–82. doi: 10.1073/pnas.0911427107
91. Zhou X, Yu S, Zhao DM, Harty JT, Badovinac VP, Xue HH. Differentiation and persistence of memory CD8+ T cells depend on T cell factor 1. Immunity (2010) 33:229–40. doi: 10.1016/j.immuni.2010.08.002
92. Sayin I, Radtke AJ, Vella LA, Jin W, Wherry EJ, Buggert M, et al. Spatial distribution and function of T follicular regulatory cells in human lymph nodes. J Exp Med. (2018) 215:20171940. doi: 10.1084/jem.20171940
93. Fu W, Liu X, Lin X, Feng H, Sun L, Li S, et al. Deficiency in T follicular regulatory cells promotes autoimmunity. J Exp Med. (2018) 215:815–25. doi: 10.1084/jem.20170901
94. Linterman MA, Pierson W, Lee SK, Kallies A, Kawamoto S, Rayner TF; et al. Foxp3+ follicular regulatory T cells control the germinal center response. Nature (2011) 471:975–82. doi: 10.1038/nm.2425
95. Chung Y, Tanaka S, Chu F, Nurieva RI, Martinez GJ, Rawal S, et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med. (2011) 17:983–8. doi: 10.1038/nm.2426
96. Wollenberg I, Aagaard-Gaard K, Seidensticker J, Hmelj R, et al. Regulation of the germinal center reaction by Foxp3+ follicular regulatory T cells. J Immunol. (2011) 187:4553–60. doi: 10.4049/jimmunol.1100937
97. Sage PT, Sharpe AH. T follicular regulatory cells. Immunity Rev. (2016) 261:9–24. doi: 10.1111/imr.12411
98. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity (2009) 30:832–44. doi: 10.1016/j.immuni.2009.04.014
99. Hofman and Mathis D. The AKT-mTOR axis regulates novo differentation of CD4+Foxp3+ cells. J Exp Med. (2008) 205:565–74. doi: 10.1084/jem.20071477
Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. *Blood* (2005) 105:4743–8. doi: 10.1182/blood-2004-10-3932

Malek TR. The biology of interleukin-2. *Annu Rev Immunol.* (2008) 26:453–79. doi: 10.1146/annurev.immunol.26.021607.090357

Botta D, Fuller MJ, Marquez-Lago TT, Bachus H, Bradley JE, Weimann AS, et al. Dynamic regulation of T follicular regulatory cell responses by interleukin 2 during influenza infection. *Nat Immunol.* (2017) 18:1249–60. doi: 10.1038/ni.3837

Xu L, Huang Q, Wang H, Hao Y, Bai Q, Hu J, et al. The Kinase mTORC1 promotes the generation and suppressive function of follicular regulatory T cells. *Immunity* (2017) 47:538–51 e5. doi: 10.1016/j.immuni.2017.08.011

Essig K, Hu D, Guimaraes JC, Alterauge D, Edelmann S, Raj T, et al. Roquin suppresses the PI3K-mTOR signaling pathway to inhibit T helper cell differentiation and conversion of treg to Tfr cells. *Immunity* (2017) 47:1067–1082 e12. doi: 10.1016/j.immuni.2017.11.00

Shekhar S, Yang X. The darker side of follicular helper T cells: from autoimmunity to immunodeficiency. *Cell Mol Immunol.* (2012) 9:380–5. doi: 10.1038/cmi.2012.26

Simpson N, Gatenby PA, Wilson A, Malik S, Fulcher DA, Tangye SG, et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. *Arthritis Rheum.* (2010) 62:234–44. doi: 10.1002/art.25032

Jung S, Gamez-Diaz L, Proietti M, Grimbacher B. “Immune TOR-opathies,” a Novel Disease Entity in Clinical Immunology, *Front Immunol* (2018) 9:966. doi: 10.3389/fimmu.2018.00966

Fruman DA, Bismuth G. Fine tuning the immune response with PI3K. *Immunol Rev.* (2009) 228:253–72. doi: 10.1111/j.1600-065X.2008.00750.x

Haylock-Jacobs S, Comerford I, Bunting M, Kara E, Townley S, Klingler-Hoffmann M, et al. PI3Kdelta drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. *J Autoimmun.* (2011) 36:278–87. doi: 10.1016/j.jaut.2011.02.006

Shrestha S, Yang K, Guy C, Vogel P, Neale G, Chi H. Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. *Nat Immunol.* (2015) 16:187–8. doi: 10.1038/ni.3076

Suzuki A, Kaisho T, Ohishi M, Tsukio-Yamaguchi M, Tsubata T, Koni PA, et al. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. *J Exp Med.* (2003) 197:657–67. doi: 10.1084/jem.20021101

Durand CA, Hartvigsen K, Fogelstrand L, Kim S, Iritani S, Vanhaesebroeck B, et al. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. *J Immunol.* (2009) 183:5673–84. doi: 10.4049/jimmunol.0900432

Jayachandran N, Mejia EM, Sheikholeslami K, Sher AA, Hou S, Hatch GM, et al. TAPP adaptors control B cell metabolism by modulating the phoshatidylinositol 3-kinase signaling pathway: a novel regulatory circuit preventing autoimmunity. *J Immunol.* (2018) 201:406–16. doi: 10.4049/jimmunol.1701440

Banham-Hall E, Clatworthy MR, Okkenhaug K. The therapeutic potential for p110k inhibitors in autoimmune rheumatic diseases. *Open Rheumatol J.* (2012) 6:245–58. doi: 10.2174/1874312901206010245

Stark AK, Sriskantharajah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. *Curr Opin Pharmacol.* (2015) 23:82–91. doi: 10.1016/j.coph.2015.05.017

Zarate-Blades CR, Horai R, Caspi RR. Regulation of autoimmunity by the microbiome. *DNA Cell Biol.* (2016) 35:455–8. doi: 10.1089/dna.2016.3432

Rao VK, Webster S, Dalm V, Sediva A, van Hagen PM, Holland S, et al. Effective ’Activated PI3Kdelta Syndrome’-targeted therapy with the PI3Kdelta inhibitor leniolisib. *Blood* (2017) 130:2307–16. doi: 10.1182/blood-2017-08-801191

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Preite, Huang, Cannons, McGavern and Schwartzberg. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.